ANI Pharmaceuticals, Inc.

ANIP

US00182C1036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:19:37 2024-04-25 am EDT			5-day change	1st Jan Change
64.62 ^USD	-1.24%		-0.18%	+16.91%

Apr. 17	Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	MT
Apr. 09	ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	CI

Ani Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

March 09, 2021 at 06:50 am EST

ANI Pharmaceuticals, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced sales was USD 57.252 million compared to USD 47.966 million a year ago. Operating income was USD 331,000 compared to operating loss of USD 4.671 million a year ago.

Net loss was USD 3.635 million compared to USD 4.835 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.41 a year ago. For the full year, sales was USD 208.475 million compared to USD 206.547 million a year ago.

Operating loss was USD 16.016 million compared to operating Income of USD 16.351 million a year ago. Net loss was USD 22.548 million compared to net income of USD 6.094 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to basic earnings per share from continuing operations of USD 0.51 a year ago.

Diluted loss per share from continuing operations was USD 1.88 compared to diluted earnings per share from continuing operations of USD 0.5 a year ago.

Latest news about ANI Pharmaceuticals, Inc.

Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	Apr. 17	MT
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	Apr. 09	CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	Apr. 03	MT
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP	Mar. 27	CI
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	Mar. 15	MT
Ani Pharmaceuticals Insider Sold Shares Worth $671,700, According to a Recent SEC Filing	Mar. 12	MT
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing	Mar. 08	MT
Ani Pharmaceuticals Insider Sold Shares Worth $456,400, According to a Recent SEC Filing	Mar. 06	MT
Ani Pharmaceuticals Insider Sold Shares Worth $330,000, According to a Recent SEC Filing	Mar. 06	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	Mar. 04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	Mar. 01	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 29	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	Feb. 29	MT
ANI Pharmaceuticals Shares Rise After Q4 Adjusted Earnings, Net Revenue Beat Forecasts	Feb. 29	MT
Transcript : ANI Pharmaceuticals, Inc., H2 2023 Earnings Call, Feb 29, 2024	Feb. 29
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $520M - $542M	Feb. 29	MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.26 - $4.67	Feb. 29	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q4 Revenue $131.7M, vs. Street Est of $124.9M	Feb. 29	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q4 EPS $1.00, vs. Street Est of $0.86	Feb. 29	MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating	Feb. 16	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,416,466, According to a Recent SEC Filing	Jan. 23	MT

Chart ANI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ANI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

65.43 USD

Average target price

79.8 USD

Spread / Average Target

+21.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANI PHARMACEUTICALS, INC.	+16.91%	1.37B
NOVO NORDISK A/S	+23.78%	562B
JOHNSON & JOHNSON	-6.16%	358B
MERCK & CO., INC.	+20.10%	322B
ABBVIE INC.	+7.93%	297B
ASTRAZENECA PLC	+13.38%	219B
NOVARTIS AG	+6.12%	199B
ROCHE HOLDING AG	-10.59%	196B
PFIZER, INC.	-10.49%	149B
AMGEN INC.	-6.20%	146B

Other Pharmaceuticals